Chen Y, Gong S, Tang J, Wang X, Gao Y, Yang H
Stem Cell Rev Rep. 2024; 21(2):509-519.
PMID: 39560864
DOI: 10.1007/s12015-024-10825-0.
Raivola J, Haikarainen T, Abraham B, Silvennoinen O
Cancers (Basel). 2021; 13(4).
PMID: 33672930
PMC: 7918039.
DOI: 10.3390/cancers13040800.
Kwon Y, Lim J, Bang S, Ha E, Hwang M, Yoon K
Ann Rheum Dis. 2020; 79(11):1438-1445.
PMID: 32723749
PMC: 7569386.
DOI: 10.1136/annrheumdis-2020-217663.
Aguilera-Diaz A, Vazquez I, Ariceta B, Manu A, Blasco-Iturri Z, Palomino-Echeverria S
PLoS One. 2020; 15(1):e0227986.
PMID: 31978184
PMC: 6980571.
DOI: 10.1371/journal.pone.0227986.
Plo I, Bellanne-Chantelot C, Mosca M, Mazzi S, Marty C, Vainchenker W
Front Endocrinol (Lausanne). 2017; 8:234.
PMID: 28955303
PMC: 5600916.
DOI: 10.3389/fendo.2017.00234.
The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders.
Maslah N, Cassinat B, Verger E, Kiladjian J, Velazquez L
Leukemia. 2017; 31(8):1661-1670.
PMID: 28484264
DOI: 10.1038/leu.2017.139.
Mutational analysis of SH2B3 in Korean patients with BCR-ABL1 negative myeloproliferative neoplasm.
Kim N, Kim I, Chang C, Lee E, Kim H, Song M
Ann Lab Med. 2015; 36(1):67-9.
PMID: 26522763
PMC: 4697347.
DOI: 10.3343/alm.2016.36.1.67.
12q24 locus association with type 1 diabetes: SH2B3 or ATXN2?.
Auburger G, Gispert S, Lahut S, Omur O, Damrath E, Heck M
World J Diabetes. 2014; 5(3):316-27.
PMID: 24936253
PMC: 4058736.
DOI: 10.4239/wjd.v5.i3.316.
LNK (SH2B3): paradoxical effects in ovarian cancer.
Ding L, Sun Q, Lin D, Chien W, Hattori N, Dong X
Oncogene. 2014; 34(11):1463-74.
PMID: 24704825
PMC: 4188804.
DOI: 10.1038/onc.2014.34.
Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis.
Spolverini A, Pieri L, Guglielmelli P, Pancrazzi A, Fanelli T, Paoli C
Haematologica. 2013; 98(9):e101-2.
PMID: 23812944
PMC: 3762108.
DOI: 10.3324/haematol.2013.090175.
Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.
Harrison C, Vannucchi A
Ther Adv Hematol. 2013; 3(6):341-54.
PMID: 23606937
PMC: 3627327.
DOI: 10.1177/2040620712459746.
SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.
Koren-Michowitz M, Gery S, Tabayashi T, Lin D, Alvarez R, Nagler A
Br J Haematol. 2013; 161(6):811-20.
PMID: 23590807
PMC: 3672250.
DOI: 10.1111/bjh.12327.
